Senolytic

How Senolytics Work

Senolytics target senescent cells through several mechanisms:

1. Pro-survival pathway inhibition - Block BCL-2 family proteins that keep senescent cells alive
2. FOXO disruption - Interfere with transcription factors protecting senescent cells
3. Apoptosis induction - Trigger programmed cell death in target cells
4. Selective targeting - Exploit unique vulnerabilities of senescent cells
5. SASP reduction - Decrease inflammatory secretions from surviving cells

Senescent cells develop resistance to normal apoptosis signals, requiring specialized compounds to eliminate them.

Relevance to Peptides

Several peptides are being researched for senolytic properties:

FOXO4-DRI Peptide

The most notable senolytic peptide:

• Mechanism - Disrupts FOXO4-p53 interaction that keeps senescent cells alive
• Selectivity - Specifically targets senescent cells
• Research - Restored fitness and fur density in aged mice (2017 study)
• Structure - D-retro-inverso peptide for enhanced stability

Other Peptide Approaches

• GHK-Cu - May reduce senescence markers (indirect senomorphic effects)
• Epithalon - Telomerase activation may reduce cellular senescence
• BPC-157 - Studied for tissue regeneration (potential senomorphic properties)

Senescence and Aging

Cellular senescence contributes to aging through:

SASP Factor	Effect	Associated Condition
IL-6	Chronic inflammation	Frailty, metabolic disease
IL-8	Immune recruitment	Tissue damage
MMP-3	Matrix degradation	Osteoarthritis, skin aging
PAI-1	Clotting dysfunction	Cardiovascular disease
VEGF	Abnormal angiogenesis	Cancer progression

Senolytics vs Senomorphics

Approach	Action	Examples
Senolytics	Kill senescent cells	FOXO4-DRI, dasatinib + quercetin
Senomorphics	Suppress SASP secretion	Rapamycin, metformin

Both strategies aim to reduce the harmful effects of senescent cells but through different mechanisms.

Current Senolytic Compounds

Peptide Senolytics

• FOXO4-DRI - Research peptide, highly selective

Small Molecule Senolytics

• Dasatinib + Quercetin (D+Q) - Most studied combination
• Fisetin - Natural flavonoid with senolytic activity
• Navitoclax (ABT-263) - BCL-2 inhibitor, platelet toxicity limits use

Research Applications

Senolytic research focuses on:

• Aging - Extending healthspan and reducing frailty
• Idiopathic pulmonary fibrosis - Removing senescent lung cells
• Osteoarthritis - Clearing senescent chondrocytes
• Atherosclerosis - Reducing vascular senescent cells
• Cancer - Eliminating therapy-induced senescence

Frequently Asked Questions

Are senolytics safe for healthy people?

Senolytic safety in healthy humans is still being established. Clinical trials are primarily in disease populations. The intermittent dosing required (senolytics don’t need daily use) may improve safety profiles. Long-term effects of periodic senescent cell clearance are unknown.

How is FOXO4-DRI different from other senolytics?

FOXO4-DRI is a peptide that specifically disrupts the FOXO4-p53 interaction that keeps senescent cells alive. This mechanism is distinct from BCL-2 inhibitors like navitoclax. The peptide showed remarkable selectivity for senescent cells in mouse studies.

How often would senolytics need to be taken?

Unlike daily medications, senolytics are designed for intermittent use. Senescent cells accumulate slowly, so periodic clearance (perhaps monthly or less frequently) may be sufficient. Current clinical trials use various intermittent dosing schedules.